Trial Profile
A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Entera Bio
- 25 Feb 2021 Primary endpoint has been met. (Peak Plasma Concentration (Cmax)of treatment), according to an Entera Bio media release.
- 25 Feb 2021 Primary endpoint has been met. (Plasma calcium levels), according to an Entera Bio media release.
- 25 Feb 2021 Primary endpoint has been met. (Reduction in use of exogenous calcium supplement and/or alpha D3 supplement), according to an Entera Bio media release.